RVLP
Income statement / Annual
Last year (2022), RVL Pharmaceuticals plc's total revenue was $49.72 M,
an increase of 184.10% from the previous year.
In 2022, RVL Pharmaceuticals plc's net income was -$51.69 M.
See RVL Pharmaceuticals plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$49.72 M |
$17.50 M |
$27.76 M |
$240.03 M |
$263.70 M |
$245.75 M |
$218.46 M |
| Cost of Revenue |
$9.46 M
|
$3.62 M
|
$3.29 M
|
$111.63 M
|
$140.08 M
|
$125.19 M
|
$125.62 M
|
| Gross Profit |
$40.27 M
|
$13.88 M
|
$24.47 M
|
$128.40 M
|
$123.62 M
|
$120.56 M
|
$92.84 M
|
| Gross Profit Ratio |
0.81
|
0.79
|
0.88
|
0.53
|
0.47
|
0.49
|
0.42
|
| Research and Development Expenses |
$3.97 M
|
$6.93 M
|
$13.39 M
|
$32.32 M
|
$43.69 M
|
$42.69 M
|
$29.06 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$81.98 M
|
$87.46 M
|
$72.82 M
|
$93.03 M
|
$74.24 M
|
$56.95 M
|
$65.96 M
|
| Other Expenses |
$6.26 M
|
-$1.33 M
|
-$48,000.00
|
$884,000.00
|
$664,391.00
|
-$4.52 M
|
$168,729.00
|
| Operating Expenses |
$85.95 M
|
$94.39 M
|
$86.21 M
|
$125.35 M
|
$117.94 M
|
$99.64 M
|
$95.02 M
|
| Cost And Expenses |
$95.40 M
|
$98.01 M
|
$89.50 M
|
$236.98 M
|
$258.02 M
|
$224.83 M
|
$220.64 M
|
| Interest Income |
$2.86 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$3.11 M
|
$4.02 M
|
$4.10 M
|
$18.21 M
|
$20.79 M
|
$29.05 M
|
$20.19 M
|
| Depreciation & Amortization |
$9.49 M
|
$6.84 M
|
$20.98 M
|
$57.02 M
|
$81.57 M
|
$46.45 M
|
$23.59 M
|
| EBITDA |
-$36.19 M |
-$73.67 M |
-$40.76 M |
$60.95 M |
-$664.39 M |
$62.85 M |
$21.58 M |
| EBITDA Ratio |
-0.73
|
-4.21
|
-1.47
|
0.25
|
0.33
|
0.26
|
0.1
|
| Operating Income Ratio |
-0.92
|
-4.6
|
-2.22
|
0.02
|
-0.37
|
-0.21
|
-0.15
|
| Total Other Income/Expenses Net |
-$6.03 M
|
$315,000.00
|
-$33.05 M
|
-$301.96 M
|
-$20.13 M
|
-$33.57 M
|
-$20.02 M
|
| Income Before Tax |
-$51.71 M
|
-$82.53 M
|
-$94.80 M
|
-$298.02 M
|
-$118.66 M
|
-$85.64 M
|
-$52.07 M
|
| Income Before Tax Ratio |
-1.04
|
-4.72
|
-3.41
|
-1.24
|
-0.45
|
-0.35
|
-0.24
|
| Income Tax Expense |
-$20,000.00
|
$315,000.00
|
-$5.78 M
|
-$27.12 M
|
-$8.98 M
|
-$40.49 M
|
-$10.25 M
|
| Net Income |
-$51.69 M
|
-$82.85 M
|
-$89.01 M
|
-$270.90 M
|
-$109.68 M
|
-$45.15 M
|
-$41.82 M
|
| Net Income Ratio |
-1.04
|
-4.73
|
-3.21
|
-1.13
|
-0.42
|
-0.18
|
-0.19
|
| EPS |
-0.58 |
-1.23 |
-1.47 |
-5.17 |
-2.42 |
-1.05 |
-0.98 |
| EPS Diluted |
-0.58 |
-1.23 |
-1.47 |
-5.17 |
-2.42 |
-0.98 |
-0.98 |
| Weighted Average Shares Out |
$89.80 M
|
$67.35 M
|
$60.65 M
|
$52.37 M
|
$45.28 M
|
$42.86 M
|
$42.85 M
|
| Weighted Average Shares Out Diluted |
$89.80 M
|
$67.35 M
|
$60.65 M
|
$52.37 M
|
$45.28 M
|
$45.86 M
|
$42.85 M
|
| Link |
|
|
|
|
|
|
|
